Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials
The mismatch runs along three axes at once: formulation (DAC versus no-DAC for CJC-1295), route (intravenous versus subcutaneous for Ipamorelin), and endpoint (GH/IGF-I pharmacodynamics or gastrointestinal recovery, versus GH-pulse modeling)
BniSchnetzler M, Schmid C, Meier PJ, Froesch ER
The conclusion was that, based on animal studies and epidemiological studies, acetaminophen exposure during infancy was a greater risk factor than in utero exposure for ASD
Closing: Storage Is the Last Line of Defense on a Peptide Protocol The clinical outcome of a peptide protocol is determined by three variables in sequence: the quality of the peptide source, the correctness of the dosing, and the integrity of the storage
2024 Feb 21;22(1):192